{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:30:42Z","timestamp":1790303442010,"version":"4.1.0"},"reference-count":233,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.neuropharm.2020.108099","type":"journal-article","created":{"date-parts":[[2020,6,7]],"date-time":"2020-06-07T10:49:05Z","timestamp":1591526945000},"page":"108099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Dual-acting agents for improving cognition and real-world function in Alzheimer\u2019s disease: Focus on 5-HT6 and D3 receptors as hubs"],"prefix":"10.1016","volume":"177","author":[{"given":"Mark J.","family":"Millan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Dekeyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Gobert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricette","family":"Brocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Mannoury la Cour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Ortuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.F.","family":"Fone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2020.108099_bib1","first-page":"15","volume":"vol. 540","author":"Abbott","year":"2016"},{"key":"10.1016\/j.neuropharm.2020.108099_bib2","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1021\/acschemneuro.7b00270","article-title":"Classics in chemical neuroscience: memantine","volume":"20","author":"Alam","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108099_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bbr.2018.04.032","article-title":"5-HT6 receptor agonist EMD386088 impairs behavioral flexibility and working memory","volume":"349","author":"Amodeo","year":"2018","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108099_bib4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.bbr.2018.11.021","article-title":"Meneses A. Intrahippocampal administration of 5-HT6 receptor drugs on memory consolidation and amnesia protocols","volume":"359","author":"Aparicio-Nava","year":"2019","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108099_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3233\/JAD-190367","article-title":"A clinical trial of transcranial electromagnetic treatment in alzheimer's disease: cognitive enhancement and associated changes in cerebrospinal fluid, blood, and brain imaging","volume":"71","author":"Arendash","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2020.108099_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2012.1162","article-title":"Alzheimer's disease: an update of the roles of receptors, astrocytes and primary cilia (review)","volume":"31","author":"Armato","year":"2013","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.neuropharm.2020.108099_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2017.20373","article-title":"Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with alzheimer disease: three randomized clinical trials","volume":"319","author":"Atri","year":"2018","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.neuropharm.2020.108099_bib8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jphs.2015.01.007","article-title":"Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range","volume":"127","author":"Baba","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108099_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1474-4422(18)30039-5","article-title":"Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study","volume":"17","author":"Ballard","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib10","first-page":"1","article-title":"DRD3 (dopamine receptor D3) but not DRD2 activates autophagy through MTORC1 inhibition preserving protein synthesis","author":"Barroso-Chinea","year":"2019","journal-title":"Autophagy"},{"key":"10.1016\/j.neuropharm.2020.108099_bib11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1124\/jpet.112.198895","article-title":"In vivo occupancy of dopamine D3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder","volume":"344","author":"Barth","year":"2013","journal-title":"J. Phamacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2020.108099_bib12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-319-62817-2_2","article-title":"CREB at the crossroads of activity-dependent regulation of nervous system development","volume":"1015","author":"Belgacem","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.trci.2019.04.002","article-title":"A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms","volume":"5","author":"Bernard","year":"2019","journal-title":"Alzheimers Dement (N Y)."},{"key":"10.1016\/j.neuropharm.2020.108099_bib14","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nrd.2016.88","article-title":"Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets","volume":"15","author":"Bespalov","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2020.108099_bib15","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.trci.2019.05.005","article-title":"Alzheimer's disease medication and risk of all-cause mortality and all-cause hospitalization: a retrospective cohort study","volume":"5","author":"Bhattacharjee","year":"2019","journal-title":"Alzheimers Dement (N Y)."},{"issue":"6","key":"10.1016\/j.neuropharm.2020.108099_bib16","first-page":"CD001190","article-title":"Dozenepil for dementia","author":"Birks","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2020.108099_bib17","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1152\/physrev.00038.2014","article-title":"mTOR in brain physiology and pathologies","volume":"95","author":"Bockaert","year":"2015","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuropharm.2020.108099_bib18","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s11064-017-2217-9","article-title":"5-HT6 receptor agonist and antagonist against \u03b2-amyloid-Peptide-Induced neurotoxicity in PC-12 cells","volume":"42","author":"Bokare","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2020.108099_bib19","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nrd.2018.109","article-title":"Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing","volume":"17","author":"Boland","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2020.108099_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0006-8993(00)02519-1","article-title":"Localization of 5-HT(6) receptors at the plasma membrane of neuronal cilia in the rat brain","volume":"872","author":"Brailov","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108099_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.brainres.2017.01.010","article-title":"5-HT6 receptor blockade regulates primary cilia morphology in striatal neurons","volume":"1660","author":"Brodsky","year":"2017","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108099_bib22","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/acel.12057","article-title":"mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies","volume":"12","author":"Caccamo","year":"2013","journal-title":"Aging Cell"},{"key":"10.1016\/j.neuropharm.2020.108099_bib23","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.neuropharm.2012.06.034","article-title":"Age-related declines in delayed non-match-to-sample performance (DNMS) are reversed by the novel 5HT6 receptor antagonist SB742457","volume":"63","author":"Callaghan","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108099_bib24","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/mp.2017.241","article-title":"Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling","author":"Cavalleri","year":"2018","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108099_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fpsyt.2018.00201","article-title":"Brain stimulation in alzheimer's disease","volume":"9","author":"Chang","year":"2018","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108099_bib26","doi-asserted-by":"crossref","first-page":"471","DOI":"10.31887\/DCNS.2010.12.4\/ycharnay","article-title":"Brain serotonergic circuitries","volume":"12","author":"Charnay","year":"2010","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108099_bib27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.tig.2019.02.005","article-title":"Progress in polygenic composite scores in alzheimer's and other complex diseases","volume":"35","author":"Chasioti","year":"2019","journal-title":"Trends Genet."},{"key":"10.1016\/j.neuropharm.2020.108099_bib28","first-page":"107839","article-title":"The 5-HT6 receptor interactome: new insight in receptor signaling and its impact on brain physiology and pathologies","volume":"1","author":"Chaumont-Dubel","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108099_bib29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00213-010-1924-6","article-title":"Imaging brain regional and cortical laminar effects of selective D3 agonists and antagonists","volume":"212","author":"Choi","year":"2010","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2020.108099_bib30","first-page":"1849794","article-title":"Social cognition dysfunctions in neurodegenerative diseases:neuroanatomical correlates and clinical implications","volume":"26","author":"Christidi","year":"2018","journal-title":"Behav. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib31","first-page":"107866","article-title":"Simultaneous activation of mGlu2 and muscarinic receptors reverses MK-801-induced cognitive decline in rodents","volume":"27","author":"Cie\u015blik","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108099_bib32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.coph.2011.01.004","article-title":"5-HT(6) receptor and cognition","volume":"11","author":"Codony","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fphar.2014.00259","article-title":"Structural plasticity in mesencephalic dopaminergic neurons produced by drugs of abuse: critical role of BDNF and dopamine","volume":"5","author":"Collo","year":"2014","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108099_bib34","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1038\/s41467-019-12280-9","article-title":"Homomeric GluA2(R) AMPA receptors can conduct when desensitized","volume":"10","author":"Coombs","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2020.108099_bib35","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/17460441.2016.1185413","article-title":"Targeting the dopamine D3 receptor: an overview of drug design strategies","volume":"11","author":"Cort\u00e9s","year":"2016","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.neuropharm.2020.108099_bib36","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/14737175.2018.1476140","article-title":"The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease","volume":"18","author":"Creese","year":"2018","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuropharm.2020.108099_bib37","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1080\/14656566.2018.1496237","article-title":"Pharmacotherapeutic strategies for treating epilepsy in patients with Alzheimer's disease","volume":"19","author":"Cretin","year":"2018","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.neuropharm.2020.108099_bib38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-030-05542-4_2","article-title":"The role of biomarkers in alzheimer's disease drug development","volume":"1118","author":"Cummings","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib39","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3233\/JAD-180766","article-title":"Treatment combinations for alzheimer's disease: current and future pharmacotherapy options","volume":"67","author":"Cummings","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2020.108099_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-020-0072-x","article-title":"Brain energy rescue: an emerging concept for new therapeutics in neurodegenerative disorders of aging","author":"Cunnane","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2020.108099_bib41","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1124\/mol.56.5.1025","article-title":"Human dopamine D(3) receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism","volume":"56","author":"Cussac","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib42","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s11064-012-0949-0","article-title":"Hippocampal neurofibromin and amyloid precursor protein expression in dopamine D3 receptor knock-out mice following passive avoidance conditioning","volume":"38","author":"D'Amico","year":"2013","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2020.108099_bib43","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/npp.2008.94","article-title":"Selective 5-HT6 receptor blockade improves spatial recognition memory and reverses age-related deficits in spatial recognition memory in the mouse","volume":"34","author":"Da Silva Costa","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108099_bib44","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bbr.2011.03.046","article-title":"Serotonin 5-HT6 receptor blockade reverses the age-related deficits of recognition memory and working memory in mice","volume":"222","author":"Da Silva Costa-Aze","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108099_bib45","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2174\/1567205013666160404120542","article-title":"Butyrylcholinesterase as a diagnostic and therapeutic target for alzheimer's disease","volume":"13","author":"Darvesh","year":"2016","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2020.108099_bib46","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1021\/cn500326z","article-title":"5-HT6 receptor: a new player controlling the development of neural circuits","volume":"6","author":"Dayer","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108099_bib47","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.2174\/1381612821666150605112105","article-title":"5-HT6 receptor antagonists: potential efficacy for the treatment of cognitive impairment in schizophrenia","volume":"21","author":"de Bruin","year":"2015","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.neuropharm.2020.108099_bib48","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.neuroscience.2007.04.045","article-title":"Acute onset by 5-HT(6)-receptor activation on rat brain brain-derived neurotrophic factor and activity-regulated cytoskeletal-associated protein mRNA expression","volume":"147","author":"de Foubert","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2020.108099_bib49","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.2174\/0929867325666180111101843","article-title":"Multi-target directed drugs as a modern approach for drug design towards alzheimer\u2019s disease: an update","volume":"25","author":"de Freitas Silva","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108099_bib50","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.neuropharm.2017.07.010","article-title":"Antagonism of the 5-HT6 receptor - preclinical rationale for the treatment of Alzheimer's disease","volume":"125","author":"de Jong","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108099_bib51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/B978-0-444-64012-3.00002-2","article-title":"Behavioral and psychological symptoms in Alzheimer's dementia and vascular dementia","volume":"165","author":"Deardorff","year":"2019","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib52","doi-asserted-by":"crossref","first-page":"12310","DOI":"10.1073\/pnas.1600914113","article-title":"Physical interaction between neurofibromin and serotonin 5-HT6 receptor promotes receptor constitutive activity","volume":"113","author":"Deraredj Nadim","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2020.108099_bib53","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1017\/S1461145706007103","article-title":"Activation of dopamine D1 receptors enhances cholinergic transmission and social cognition: a parallel dialysis and behavioural study in rats","volume":"10","author":"Di Cara","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib54","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.freeradbiomed.2017.08.009","article-title":"mTOR in Down syndrome: role in Amyloid and tau neuropathology and transition to Alzheimer disease-like dementia","volume":"114","author":"Di Domenico","year":"2018","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108099_bib55","first-page":"126","article-title":"Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials Alzheimers","volume":"10","author":"Dou","year":"2018","journal-title":"Respir. Ther."},{"key":"10.1016\/j.neuropharm.2020.108099_bib56","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00401-016-1662-x","article-title":"Alzheimer's disease: experimental models and reality","volume":"133","author":"Drummond","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib57","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nchembio.1547","article-title":"Cdk5 induces constitutive activation of 5-HT6 receptors to promote neurite growth","volume":"10","author":"Duhr","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib58","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejphar.2008.04.039","article-title":"Actions of novel agonists, antagonists and antipsychotic agents at recombinant rat 5-HT6 receptors: a comparative study of coupling to G alphas","volume":"588","author":"Dupuis","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib59","doi-asserted-by":"crossref","unstructured":"Egeland M., Zhang X., Millan M.J, Mocaer E, Svenningsson P. Pharmacological or genetic blockade of the dopamine D3 receptor increases cell proliferation in the hippocampus of adult mice. J. Neurochem.. 123, 811-823.","DOI":"10.1111\/jnc.12011"},{"key":"10.1016\/j.neuropharm.2020.108099_bib60","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pharmthera.2019.03.005","article-title":"Gene-environment interactions in Alzheimer's disease: a potential path to precision medicine","volume":"199","author":"Eid","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2020.108099_bib61","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neuroscience.2015.04.046","article-title":"The 5-HT6 receptor interactome: new insight in receptor signaling and its impact on brain physiology and pathologies","volume":"299","author":"Eskenazi","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2020.108099_bib62","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40263-016-0399-3","article-title":"Serotonin 5-HT6 receptor antagonists in alzheimer's disease: therapeutic rationale and current development status","volume":"31","author":"Ferrero","year":"2017","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.neuropharm.2020.108099_bib63","first-page":"62","article-title":"Prefrontal dopamine and behavioral flexibility: shifting from an \u201cinverted-U\u201d toward a family of functions","volume":"19","author":"Floresco","year":"2013","journal-title":"Front Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108099_bib64","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.npp.1300332","article-title":"The 5-HT(6) receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats","volume":"29","author":"Foley","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108099_bib65","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.neuropharm.2008.03.012","article-title":"The selective 5-HT6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats","volume":"54","author":"Foley","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108099_bib66","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.neuropharm.2008.06.061","article-title":"An update on the role of the 5-hydroxytryptamine(6) receptor in cognitive function","volume":"55","author":"Fone","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108099_bib67","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/cercor\/bhr130","article-title":"Glial D-serine gates NMDA receptors at excitatory synapses in prefrontal cortex","volume":"22","author":"Fossat","year":"2012","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2020.108099_bib68","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1586\/ern.12.124","article-title":"Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease","volume":"12","author":"Francis","year":"2012","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuropharm.2020.108099_bib69","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1093\/brain\/awz150","article-title":"EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease. Alzheimer's Disease Neuroimaging Initiative","volume":"142","author":"Gaubert","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2020.108099_bib70","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1007\/s00213-016-4382-y","article-title":"Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3\/D2 receptor ligand [(11)C]-(+)-PHNO","volume":"233","author":"Girgis","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108099_bib71","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2174\/156802610791111542","article-title":"The medicinal chemistry of 5-HT6 receptor ligands with a focus on arylsulfonyltryptamine analogs","volume":"10","author":"Glennon","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108099_bib72","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/cercor\/bhh202","article-title":"Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention","volume":"15","author":"Glickstein","year":"2005","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2020.108099_bib73","first-page":"234","article-title":"Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials","volume":"24","author":"Gold","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neuropharm.2020.108099_bib74","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00210-012-0806-3","article-title":"Dopamine D\u2083 receptor antagonism-still a therapeutic option for the treatment of schizophrenia","volume":"386","author":"Gross","year":"2013","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib75","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1021\/acschemneuro.6b00090","article-title":"Novel 1H-Pyrrolo[3,2-c]quinolone based 5-HT6 receptor antagonists with potential application for the treatment of cognitive disorders associated with alzheimer's disease","volume":"7","author":"Grychowska","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108099_bib76","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1021\/acschemneuro.8b00618","article-title":"Dual 5-HT6 and D3 receptor antagonists in a group of 1H-Pyrrolo[3,2-c]quinolines with neuroprotective and procognitive activity","volume":"10","author":"Grychowska","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108099_bib77","doi-asserted-by":"crossref","first-page":"7850","DOI":"10.1038\/s41598-019-43955-4","article-title":"Role of D3 dopamine receptors in modulating neuroanatomical changes in response to antipsychotic administration","volume":"24","author":"Guma","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2020.108099_bib78","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3233\/JAD-181231","article-title":"LY379268 does not have long-term procognitive effects nor attenuate glutamatergic signaling in A\u03b2PP\/PS1 mice","volume":"68","author":"Hascup","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2020.108099_bib79","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3389\/fnagi.2019.00148","volume":"11","author":"Hatat","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108099_bib80","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.neuroscience.2015.09.064","article-title":"Distribution of serotonin receptor 5-HT6 mRNA in rat neuronal subpopulations: a double in situ hybridization study","volume":"310","author":"Helboe","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2020.108099_bib81","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrneurol.2015.229","article-title":"Clinical assessment of social cognitive function in neurological disorders","volume":"12","author":"Henry","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib82","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.lfs.2009.01.019","article-title":"Procognitive 5-HT6 antagonists in the rat forced swimming test: potential therapeutic utility in mood disorders associated with Alzheimer's disease","volume":"84","author":"Hirano","year":"2009","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2020.108099_bib83","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1124\/mol.64.6.1295","article-title":"Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling","volume":"64","author":"Hirst","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib84","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejphar.2006.09.049","article-title":"SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models","volume":"553","author":"Hirst","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib85","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jchemneu.2003.10.002","article-title":"The human raphe nuclei and the serotonergic system","volume":"26","author":"Hornung","year":"2003","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.neuropharm.2020.108099_bib86","doi-asserted-by":"crossref","unstructured":"Hounsou, C, Margather, JF, Oueslati, N, Belhocine A, Dupuis E, Thomas C, Mann A, Ilien B, Rognan D, Trinquet E, Hibert M, Pin JP, Bonnet D, Durroux T. 2015Time-resolved FRET binding assay to investigate hetero-oligomer binding properties: proof of concept with dopamine D1\/D3 heterodimer. ACS Chem. Biol.;10, 466-474.","DOI":"10.1021\/cb5007568"},{"key":"10.1016\/j.neuropharm.2020.108099_bib87","article-title":"Questions EMERGE as Biogen claims aducanumab turnaround","volume":"29","author":"Howard","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib88","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13195-017-0304-4","article-title":"Serotonin 5-HT6 receptors affect cognition in a mouse model of Alzheimer's disease by regulating cilia function","volume":"9","author":"Hu","year":"2017","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuropharm.2020.108099_bib89","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pbb.2015.09.011","article-title":"Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement","volume":"138","author":"Huang","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2020.108099_bib90","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fnins.2016.00177","article-title":"One for all? Hitting multiple alzheimer's disease targets with one drug","volume":"10","author":"Hughes","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108099_bib91","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1254\/jphs.13036FP","article-title":"Stimulation of metabotropic glutamate (mGlu) 2 receptor and blockade of mGlu1 receptor improve social memory impairment elicited by MK-801 in rats","volume":"122","author":"Ikichi","year":"2013","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108099_bib92","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.jalz.2018.08.004","article-title":"The clinical practice of risk reduction for Alzheimer's disease: a precision medicine approach","volume":"14","author":"Isaacson","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neuropharm.2020.108099_bib93","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.neulet.2018.05.039","article-title":"The plastic d-serine signaling pathway: sliding from neurons to glia and vice-versa","volume":"689","author":"Ivanov","year":"2019","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2020.108099_bib94","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1471-4159.2007.04840.x","article-title":"Dopamine D(1) and D(3) receptors oppositely regulate NMDA- and cocaine-induced MAPK signaling via NMDA receptor phosphorylation","volume":"103","author":"Jiao","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2020.108099_bib95","doi-asserted-by":"crossref","first-page":"l6217","DOI":"10.1136\/bmj.l6217","article-title":"Cognitive symptoms of Alzheimer's disease: clinical management and prevention","volume":"367","author":"Joe","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.neuropharm.2020.108099_bib96","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/CIA.S129145","article-title":"Rivastigmine: the advantages of dual inhibition of cetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia","volume":"12","author":"Kandiah","year":"2017","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.neuropharm.2020.108099_bib97","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.nbd.2015.08.005","article-title":"The interneuron energy hypothesis: implications for brain disease","volume":"90","author":"Kann","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2020.108099_bib98","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00213-010-1854-3","article-title":"E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat","volume":"213","author":"Kendall","year":"2011","journal-title":"Psychopharmacology (Berlin)"},{"issue":"7","key":"10.1016\/j.neuropharm.2020.108099_bib99","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4080","article-title":"Association of concomitant use of cholinesterase inhibitors or memantine with cognitive decline in alzheimer clinical trials: a meta-analysis","volume":"1","author":"Kennedy","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.neuropharm.2020.108099_bib100","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/13543784.2018.1483334","article-title":"The role of 5 HT6 receptor antagonists in Alzheimer's disease: an update","volume":"27","author":"Khoury","year":"2018","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.neuropharm.2020.108099_bib101","article-title":"Direct interaction and functional coupling between human 5-HT6 receptor and the light chain 1 subunit of the microtubule-associated protein 1B (MAP1B-LC1)","volume":"9","author":"Kim","year":"2014","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108099_bib102","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s11515-015-1360-4","article-title":"New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease","volume":"10","author":"Kim","year":"2015","journal-title":"Front. Biol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib103","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuropharm.2004.03.012","article-title":"5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation - an effect sensitive to NMDA receptor antagonism","volume":"47","author":"King","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108099_bib104","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.tips.2008.07.001","article-title":"A role for the 5-HT1A, 5-HT4 and 5-HT6 receptors in learning and memory","volume":"29","author":"King","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108099_bib105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.neulet.2015.05.056","article-title":"Multiple actions of a D\u2083 dopamine receptor agonist, PD128907, on GABAergic inhibitory transmission between medium spiny neurons in mouse nucleus accumbens shell","volume":"300","author":"Kohnomi","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2020.108099_bib106","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bbr.2016.02.031","article-title":"The atypical antipsychotic blonanserin reverses (+)-PD-128907- and ketamine-induced deficit in executive function in common marmosets","volume":"305","author":"Kotani","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108099_bib107","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1111\/bph.14329","article-title":"Galantamine is not a positive allosteric modulator of human \u03b14\u03b22 or \u03b17 nicotinic acetylcholine receptors","volume":"175","author":"Kowal","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib108","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5056\/jnm18087","article-title":"Brain-gut-microbiota Axis in alzheimer's disease","volume":"25","author":"Kowalski","year":"2019","journal-title":"J. Neurogastroenterol. Motil."},{"key":"10.1016\/j.neuropharm.2020.108099_bib109","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejmech.2014.12.045","article-title":"Novel 5-HT6 receptor antagonists\/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia","volume":"92","author":"Ko\u0142aczkowski","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108099_bib110","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3233\/JAD-150393","article-title":"Histamine H3 receptor antagonists for alzheimer's disease: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"48","author":"Kubo","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2020.108099_bib111","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3233\/JAD-170991","article-title":"The alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog): modifications and responsiveness in pre-dementia populations. A narrative review","volume":"63","author":"Kueper","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2020.108099_bib112","doi-asserted-by":"crossref","first-page":"781","DOI":"10.4155\/fmc-2017-0031","article-title":"Modulating 5-HT4 and 5-HT6 receptors in Alzheimer's disease treatment","volume":"9","author":"Lalut","year":"2017","journal-title":"Future Med. Chem."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108099_bib113","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.trci.2017.07.001","article-title":"Neuropsychiatric signs and symptoms of Alzheimer's disease: new treatment paradigms","volume":"3","author":"Lanct\u00f4t","year":"2017","journal-title":"Alzheimers Dement (N Y)."},{"key":"10.1016\/j.neuropharm.2020.108099_bib114","doi-asserted-by":"crossref","first-page":"E3825","DOI":"10.1073\/pnas.1410315111","article-title":"Design of donecopride, a dual serotonin subtype 4 receptor agonist\/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment","volume":"111","author":"Lecoutey","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2020.108099_bib115","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1021\/acs.jmedchem.5b00115","article-title":"Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride","volume":"58","author":"Legay","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108099_bib116","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.pharmthera.2016.06.007","article-title":"Current drug treatments targeting dopamine D3 receptor","volume":"165","author":"Leggio","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2020.108099_bib117","article-title":"The epistatic interaction between the dopamine D3 receptor and dysbindin-1 modulates higher-order cognitive functions in mice and humans","author":"Leggio","year":"2019","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108099_bib118","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1124\/mol.117.111583","article-title":"Restoration of physiological expression of 5-HT6 receptor into the primary cilia of null mutant neurons lengthens both primary cilia and dendrites","volume":"94","author":"Lesiak","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib119","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","article-title":"Tau PET imaging in neurodegenerative tauopathies-still a challenge","volume":"24","author":"Leuzy","year":"2019","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108099_bib120","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00429-012-0383-8","article-title":"Molecular characterization of individual D3 dopamine receptor-expressing cells isolated from multiple brain regions of a novel mouse model","volume":"217","author":"Li","year":"2012","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.neuropharm.2020.108099_bib121","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s12031-018-1238-4","article-title":"Over-expression of 5-HT6 receptor and activated jab-1\/p-c-jun play important roles in pilocarpine-induced seizures and learning-memory impairment","volume":"67","author":"Liu","year":"2019","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108099_bib122","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.euroneuro.2008.07.012","article-title":"Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists","volume":"19","author":"Loiseau","year":"2009","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2020.108099_bib123","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00213-007-0934-5","article-title":"Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex","volume":"196","author":"Loiseau","year":"2008","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2020.108099_bib124","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/B978-0-12-804766-8.00009-1","article-title":"Epidemiology of aging and associated cognitive disorders: prevalence and incidence of Alzheimer's disease and other dementias","volume":"167","author":"Lopez","year":"2019","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib125","doi-asserted-by":"crossref","first-page":"156","DOI":"10.12779\/dnd.2018.17.4.156","article-title":"Association of alzheimer's disease with the risk of developing epilepsy: a 10-year nationwide cohort study","volume":"17","author":"Lyou","year":"2019","journal-title":"Dement Neurocogn. Disord."},{"issue":"Suppl. 4","key":"10.1016\/j.neuropharm.2020.108099_bib126","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1353-8020(09)70826-0","article-title":"Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance","volume":"15","author":"Maggio","year":"2009","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2020.108099_bib127","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.trci.2015.04.001","article-title":"Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease","volume":"1","author":"Maher-Edwards","year":"2015","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.neuropharm.2020.108099_bib128","first-page":"451","article-title":"Dopamine D3 receptor antagonists as potential therapeutics for the treatment of neurological diseases","volume":"10","author":"Maramai","year":"2015","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108099_bib129","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s11064-011-0684-y","article-title":"Distribution of serotonin receptor of type 6 (5-HT\u2086) in human brain post-mortem. A pharmacology, autoradiography and immunohistochemistry study","volume":"37","author":"Marazziti","year":"2012","journal-title":"Neurochem. Res."},{"issue":"7","key":"10.1016\/j.neuropharm.2020.108099_bib130","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201900041","article-title":"Anti-Alzheimer's multitarget-directed ligands with serotonin 5-HT6 antagonist, butyrylcholinesterase inhibitory, and antioxidant activity","volume":"352","author":"Marcinkowska","year":"2019","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.neuropharm.2020.108099_bib131","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/138945012798868498","article-title":"5-HT receptor-associated protein networks: new targets for drug discovery in psychiatric disorders?","volume":"13","author":"Marin","year":"2012","journal-title":"Curr. Drug Targets"},{"issue":"5","key":"10.1016\/j.neuropharm.2020.108099_bib132","first-page":"18","article-title":"Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis","volume":"18","author":"Matsunaga","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib133","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1017\/S1041610218002156","article-title":"Efficacy and safety of idalopirdine for Alzheimer's disease: a systematic review and meta-analysis","volume":"31","author":"Matsunaga","year":"2019","journal-title":"Int. Psychogeriatr."},{"key":"10.1016\/j.neuropharm.2020.108099_bib134","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neuroimage.2016.02.002","article-title":"Age-related changes in binding of the D2\/3 receptor radioligand [(11)C](+)PHNO in healthy volunteers","volume":"130","author":"Matuskey","year":"2016","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuropharm.2020.108099_bib135","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3233\/JAD-170541","article-title":"What can quantitative gait analysis tell us about dementia and its subtypes? A Structured Review","volume":"60","author":"McArdle","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2020.108099_bib136","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/HRP.0000000000000097","article-title":"Interventions for neuropsychiatric symptoms in neurocognitive impairment due to alzheimer's disease: a review of the literature","volume":"23","author":"McClam","year":"2015","journal-title":"Harv. Rev. Psychiatr."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108099_bib137","first-page":"CD00315","article-title":"Memantine for dementia","volume":"20","author":"McShane","year":"2019","journal-title":"Cochrane Database Syst. Rev. Mar"},{"key":"10.1016\/j.neuropharm.2020.108099_bib138","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/emmm.201201410","article-title":"5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia","volume":"4","author":"Meffre","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.neuropharm.2020.108099_bib139","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.neuropharm.2009.08.017","article-title":"The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats","volume":"58","author":"Mela","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108099_bib140","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-642-25761-2_4","article-title":"Serotonergic mechanisms as targets for existing and novel antipsychotics","volume":"212","author":"Meltzer","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib141","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.phrs.2010.02.003","article-title":"Enhanced cognitive performance of dopamine D3 receptor \u201cknock-out\u201d mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid\/endovanilloid systems","volume":"61","author":"Micale","year":"2010","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2020.108099_bib142","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2005.11.006","article-title":"Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application","volume":"110","author":"Millan","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2020.108099_bib143","series-title":"Animal and Translational Models for CNS Drug Discovery","first-page":"483","article-title":"The discovery and development of pharmacotherapy for psychiatric disorders: a critical survey of animal and translational models and perspectives for their improvement pp 1-57","author":"Millan","year":"2008"},{"key":"10.1016\/j.neuropharm.2020.108099_bib144","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1017\/S1461145712001496","article-title":"On 'polypharmacy' and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal","volume":"17","author":"Millan","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2017.03.004","article-title":"Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer's disease: an integrative review","volume":"156","author":"Millan","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib146","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2515\/therapie:2008041","article-title":"Cognitive impairment in schizophrenia: a review of developmental and genetic models, and procognitive profile of the optimised D(3) 4 D(2) antagonist, S33138","volume":"63","author":"Millan","year":"2008","journal-title":"Therapie"},{"key":"10.1016\/j.neuropharm.2020.108099_bib147","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0022-3565(24)39332-2","article-title":"S33084, a novel, potent, selective, and competitive antagonist at dopamine D-3-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR 218, 231 and L741,626","volume":"293","author":"Millan","year":"2000","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108099_bib148","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1471-4159.2006.04262.x","article-title":"Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis","volume":"10","author":"Millan","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2020.108099_bib149","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1124\/jpet.107.134536","volume":"324","author":"Millan","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108099_bib150","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.tips.2008.06.007","article-title":"Signaling at G-protein coupled serotonin receptors: recent advances and future research directions","volume":"29","author":"Millan","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108099_bib151","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1124\/jpet.107.132563","volume":"324","author":"Millan","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108099_bib152","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1017\/S1461145710000775","article-title":"The dopamine D(3) receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures","volume":"13","author":"Millan","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib153","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrd3628","article-title":"Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy","volume":"11","author":"Millan","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2020.108099_bib154","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.euroneuro.2015.01.016","article-title":"Learning from the past and looking to the future: emerging perspectives for improving the treatment of psychiatric disorders","volume":"25","author":"Millan","year":"2015","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2020.108099_bib155","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1177\/0269881116672342","article-title":"The frontal cortex as a network hub controlling mood and cognition: probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders","volume":"30","author":"Millan","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib156","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/10799893.2010.506192","article-title":"The neurobiology of dopamine receptors: evolution from the dual concept to heterodimer complexes","volume":"30","author":"Missale","year":"2010","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"10.1016\/j.neuropharm.2020.108099_bib157","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00401-018-1932-x","article-title":"Current state of Alzheimer's fluid biomarkers","volume":"136","author":"Molinuevo","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib158","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1358\/dot.2010.46.3.1437247","article-title":"Serotonin 5-HT(2A) receptor antagonists in the treatment of insomnia: present status and future prospects","volume":"46","author":"Monti","year":"2010","journal-title":"Drugs Today"},{"key":"10.1016\/j.neuropharm.2020.108099_bib159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2017.02.010","article-title":"Effects of the 5-HT6 receptor antagonist idalopirdine on extracellular levels of monoamines, glutamate and acetylcholine in the rat medial prefrontal cortex","volume":"799","author":"M\u00f8rk","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib160","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3389\/fnins.2018.01017","article-title":"Tau and mTOR: the hotspots for multifarious diseases in alzheimer's development","volume":"12","author":"Mueed","year":"2018","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108099_bib161","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1002\/cpph.57","article-title":"Preclinical models of alzheimer's disease: relevance and translational validity","volume":"84","author":"Mullane","year":"2019","journal-title":"Curr. Protoc. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib162","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.euroneuro.2013.05.006","article-title":"The potential role of dopamine D\u2083 receptor neurotransmission in cognition","volume":"23","author":"Nakajima","year":"2013","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2020.108099_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2018.11.040","article-title":"Harnessing genetic complexity to enhance translatability of alzheimer's disease mouse models: a path toward precision medicine","volume":"101","author":"Neuner","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2020.108099_bib164","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S0026-895X(24)12183-9","article-title":"G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: a guanosine-5'-O-(3-[35S]thio)- triphosphate binding and antibody study","volume":"55","author":"Newman-Tancredi","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib165","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","article-title":"A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial","volume":"385","author":"Ngandu","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2020.108099_bib166","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1515\/revneuro-2014-0005","article-title":"The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia","volume":"25","author":"Nikiforuk","year":"2014","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108099_bib167","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/0269881113480991","article-title":"The 5-hydroxytryptamine (serotonin) receptor 6 agonist EMD 386088 ameliorates ketamine-induced deficits in attentional set shifting and novel object recognition, but not in the prepulse inhibition in rats","volume":"27","author":"Nikiforuk","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib168","series-title":"RICT 2016: 52nd International Conference on Medicinal Chemistry","article-title":"Discovery of dopaminergic D3 receptor antagonists with potent 5HT6 affinity","author":"Ortuno","year":"2016"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108099_bib169","doi-asserted-by":"crossref","first-page":"12932","DOI":"10.1038\/s41598-019-49275-x","article-title":"Novel method for rapid assessment of cognitive impairment using high-performance eye-tracking technology","volume":"9","author":"Oyama","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2020.108099_bib170","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3389\/fnagi.2019.00175","article-title":"Dopamine and dopamine receptors in alzheimer's disease: a systematic review and network meta-analysis","volume":"11","author":"Pan","year":"2015","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108099_bib171","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2174\/1567205016666190321154618","article-title":"Systemic and CNS inflammation crosstalk: implications for alzheimer's disease","volume":"16","author":"Paouri","year":"2019","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2020.108099_bib172","first-page":"2571","article-title":"Dopaminergic mechanisms in memory consolidation and antidepressant reversal of a chronic mild stress-induced cognitive impairment Psychopharmacology (Berl)","volume":"234","author":"Papp","year":"2017"},{"key":"10.1016\/j.neuropharm.2020.108099_bib173","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1177\/0269881119827889","article-title":"The role of prefrontal cortex dopamine D2 and D3 receptors in the mechanism of action of venlafaxine and deep brain stimulation in animal models of treatment-responsive and treatment-resistant depression","volume":"33","author":"Papp","year":"2019","journal-title":"J. Psychopharmacol."},{"issue":"44","key":"10.1016\/j.neuropharm.2020.108099_bib174","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.3346\/jkms.2019.34.e293","article-title":"Decline in the incidence of all-cause and alzheimer's disease dementia: a 12-year-later rural cohort study in Korea","volume":"8","author":"Park","year":"2019","journal-title":"J. Kor. Med. Sci."},{"key":"10.1016\/j.neuropharm.2020.108099_bib175","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2967\/jnumed.111.093419","article-title":"Human kinetic modeling of the 5HT6 PET radioligand 11C-GSK215083 and its utility for determining occupancy at both 5HT6 and 5HT2A receptors by SB742457 as a potential therapeutic mechanism of action in alzheimer disease","volume":"53","author":"Parker","year":"2012","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.neuropharm.2020.108099_bib176","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.2967\/jnumed.115.162743","article-title":"Human kinetic modeling of the 5HT6 PET radioligand 11C-GSK215083 and its utility for determining occupancy at both 5HT6 and 5HT2A receptors by SB742457 as a potential therapeutic mechanism of action in alzheimer disease","volume":"56","author":"Parker","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.neuropharm.2020.108099_bib177","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.biopsych.2019.01.006","article-title":"Synapse-to-nucleus signaling in neurodegenerative and neuropsychiatric Disorders","volume":"86","author":"Parras-Damas","year":"2019","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108099_bib178","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0028-3908(99)00019-2","article-title":"Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data","volume":"38","author":"Parsons","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108099_bib179","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12640-013-9398-z","article-title":"Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease","volume":"24","author":"Parsons","year":"2013","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2020.108099_bib180","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1093\/schbul\/sbx089","article-title":"Motor abnormalities: from neurodevelopmental to neurodegenerative through \u201cfunctional\u201d (Neuro)Psychiatric disorders","volume":"43","author":"Peralta","year":"2017","journal-title":"Schizophr. Bull."},{"issue":"8","key":"10.1016\/j.neuropharm.2020.108099_bib181","first-page":"e1278","article-title":"Current state of Digital Biomarker Technologies for real-life, home-based monitoring of cognitive function for Mild Cognitive Impairment to mild Alzheimer Disease and implications for clinical care; a systematic Review","volume":"21","author":"Piau","year":"2018","journal-title":"J. Med. Internet Res."},{"key":"10.1016\/j.neuropharm.2020.108099_bib182","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neubiorev.2018.09.012","article-title":"Social brain, social dysfunction and social withdrawal","volume":"97","author":"Porcelli","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2020.108099_bib183","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/13543784.2017.1364360","article-title":"Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease","volume":"26","author":"Prickaerts","year":"2017","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.neuropharm.2020.108099_bib184","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2967\/jnumed.117.206516","article-title":"Age-related change in 5-HT6 receptor availability in healthy male volunteers measured with 11C-GSK215083 PET","volume":"59","author":"Radhakrishnan","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.neuropharm.2020.108099_bib185","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/alzrt169","article-title":"5-HT6 receptors and Alzheimer's disease","volume":"5","author":"Ramirez","year":"2013","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuropharm.2020.108099_bib186","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1017\/S1461145713000412","article-title":"Considerations in psychotropic treatments in dementia--can polypharmacy be avoided?","volume":"17","author":"Ravona-Springer","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib187","doi-asserted-by":"crossref","unstructured":"Rochais C., Lecoutey C., Gaven F., Giannoni P., Hamidouche K., Hedou D., Dubost E., Genest D., Yahiaoui S., Freret T., Bouet V., Dauphin F., Sopkova de Oliveira Santos J., Ballandonne C., Corvaisier S., Malzert-Fr\u00e9on A. Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride. J. Med. Chem.. 58, 3172-3187.","DOI":"10.1021\/acs.jmedchem.5b00115"},{"key":"10.1016\/j.neuropharm.2020.108099_bib188","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jad.2017.07.042","article-title":"NK1 receptor antagonists for depression: why a validated concept was abandoned","volume":"223","author":"Rupniak","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2020.108099_bib189","doi-asserted-by":"crossref","first-page":"146375","DOI":"10.1016\/j.brainres.2019.146375","article-title":"5-HT6 receptor agonist and antagonist improve memory impairments and hippocampal BDNF signaling alterations induced by MK-801","volume":"1722","author":"Rychtyk","year":"2019","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108099_bib190","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s13311-019-00755-y","article-title":"Consequences of metabolic disruption in alzheimer's disease pathology","volume":"16","author":"Ryu","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2020.108099_bib191","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bmc.2016.10.010","article-title":"Design and synthesis of novel N-sulfonyl-2-indoles that behave as 5-HT6 receptor ligands with significant selectivity for D3 over D2 receptors","volume":"25","author":"Saavedra","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108099_bib192","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bmc.2016.10.010","article-title":"Design and synthesis of novel N-sulfonyl-2-indoles that behave as 5-HT6 receptor ligands with significant selectivity for D3 over D2 receptors","volume":"25","author":"Saavedra","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108099_bib193","first-page":"13","article-title":"FDA position statement \u201cEarly Alzheimer's disease: developing drugs for treatment, Guidance for Industry\u201d","volume":"10","author":"Sabbagh","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"215","key":"10.1016\/j.neuropharm.2020.108099_bib194","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jep.2017.12.015","article-title":"Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease","volume":"6","author":"Sahoo","year":"2018","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib195","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3389\/fneur.2019.00490","article-title":"Development of a multicomponent intervention to prevent alzheimer's disease","volume":"10","author":"Saito","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib196","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev-neuro-070815-014015","article-title":"Alzheimer's disease mechanisms and emerging roads to novel therapeutics","volume":"39","author":"Sala Frigerio","year":"2016","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108099_bib197","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","article-title":"Alzheimer's disease","volume":"388","author":"Scheltens","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2020.108099_bib198","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/ene.12707","article-title":"EFNS-ENS\/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease","volume":"22","author":"Schmidt","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib199","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2020.108099_bib200","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/ejn.13390","article-title":"The dopamine D3 receptor, a quarter century later","volume":"45","author":"Sokoloff","year":"2017","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108099_bib201","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00210-012-0797-0","article-title":"Direct and indirect interactions of the dopamine D\u2083 receptor with glutamate pathways: implications for the treatment of schizophrenia","volume":"386","author":"Sokoloff","year":"2013","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib202","first-page":"11185","article-title":"Virtual screening-driven discovery of dual 5-HT6\/5-HT2A receptor ligands with pro-cognitive properties","author":"Staro\u0144","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108099_bib203","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.neurobiolaging.2019.09.005","article-title":"Co-activation of selective nicotinic acetylcholine receptors is required to reverse beta amyloid-induced Ca2+ hyperexcitation","volume":"84","author":"Sun","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2020.108099_bib204","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hipo.20408","article-title":"Postsynaptic dopamine D3 receptor modulation of evoked IPSCs via GABA(A) receptor endocytosis in rat hippocampus","volume":"18","author":"Swant","year":"2008","journal-title":"Hippocampus"},{"key":"10.1016\/j.neuropharm.2020.108099_bib205","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.neuint.2019.04.008","article-title":"Blonanserin ameliorates social deficit through dopamine-D3 receptor antagonism in mice administered phencyclidine as an animal model of schizophrenia","volume":"128","author":"Takeuchi","year":"2019","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2020.108099_bib206","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/ijnp\/pyy004","article-title":"Comparison of dopamine D3 and D2 receptor occupancies by a single dose of blonanserin in healthy subjects: a positron emission Tomography study with [11C]-(+)-PHNO","volume":"21","author":"Tateno","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib207","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2007097","article-title":"Serotonin receptor HTR6-mediated mTORC1 signaling regulates dietary restriction-induced memory enhancement","volume":"17","author":"Teng","year":"2019","journal-title":"PLoS Biol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib208","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/jgs.15069","article-title":"Comparative effectiveness and safety of cognitive enhancers for treating alzheimer's disease: systematic review and network metaanalysis","volume":"66","author":"Tricco","year":"2018","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.neuropharm.2020.108099_bib209","first-page":"3370","article-title":"Alzheimer's disease: a systemic review of substantial therapeutic targets and the leading multi-functional molecules","volume":"217","author":"Umar","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108099_bib210","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1093\/advances\/nmz054","article-title":"The mediterranean, dietary approaches to stop hypertension (DASH), and mediterranean-DASH intervention for neurodegenerative delay (MIND) diets are associated with less cognitive decline and a lower risk of alzheimer's disease-A review","volume":"10","author":"Van den Brink","year":"2019","journal-title":"Adv. Nutr."},{"key":"10.1016\/j.neuropharm.2020.108099_bib211","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/j.1471-4159.2006.04141.x","article-title":"Multifunctional drugs with different CNS targets for neuropsychiatric disorders","volume":"99","author":"Van der Schyf","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2020.108099_bib212","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neubiorev.2019.07.019","article-title":"Alzheimer's disease: neurotransmitters of the sleep-wake cycle","volume":"105","author":"Van Erum","year":"2019","journal-title":"Nurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2020.108099_bib213","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jalz.2018.08.005","article-title":"Understanding disease progression and improving Alzheimer's disease clinical trials: recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's Disease Neuroimaging Initiative","volume":"15","author":"Veitch","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neuropharm.2020.108099_bib214","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/jphp.12919","article-title":"Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy","volume":"70","author":"Verma","year":"2018","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib215","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.nbd.2008.11.010","article-title":"Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease","volume":"35","author":"Visanji","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2020.108099_bib216","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tins.2019.11.002","article-title":"Neocortex-Cerebellum circuits for cognitive processing","volume":"43","author":"Wagner","year":"2020","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108099_bib217","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s12035-014-8806-6","article-title":"5-HT6 receptor recruitment of mTOR modulates seizure activity in epilepsy","volume":"51","author":"Wang","year":"2015","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib218","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1017\/S1461145711000435","article-title":"Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment","volume":"15","author":"Watson","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib219","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/npp.2011.254","article-title":"Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex","volume":"37","author":"Watson","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108099_bib220","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1734-1140(10)70315-7","article-title":"Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data","volume":"62","author":"Weso\u0142owska","year":"2010","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neuropharm.2020.108099_bib221","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1517\/13543784.2015.1102884","article-title":"Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease","volume":"24","author":"Wicke","year":"2015","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.neuropharm.2020.108099_bib222","first-page":"195","article-title":"Novel multitarget-directed ligands aiming at symptoms and causes of alzheimer's disease","volume":"16","author":"Wi\u0119ckowska","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108099_bib223","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.drudis.2018.11.007","article-title":"A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate\/GABA neurotransmitter systems","volume":"24","author":"Wilkinson","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.neuropharm.2020.108099_bib224","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S1474-4422(14)70198-X","article-title":"Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"13","author":"Wilkinson","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib225","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.dadm.2019.02.006","article-title":"Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer's Coordinating Centers volunteers","volume":"11","author":"Wise","year":"2019","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.neuropharm.2020.108099_bib226","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1476-5381.2012.02022.x","article-title":"5-HT(6) receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms","volume":"167","author":"Woods","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108099_bib227","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0028-3908(01)00056-9","article-title":"A role for 5-ht(6) receptors in retention of spatial learning in the Morris water maze","volume":"41","author":"Woolley","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108099_bib228","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.neulet.2010.06.071","article-title":"Influence of dopamine D3 receptor knockout on age-related decline of spatial memory","volume":"481","author":"Xing","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2020.108099_bib229","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejmech.2016.05.048","article-title":"Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease","volume":"121","author":"Yahiaoui","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108099_bib230","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1074\/jbc.M606215200","article-title":"The novel cellular mechanism of human 5-HT6 receptor through an interaction with Fyn","volume":"282","author":"Yun","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2020.108099_bib231","doi-asserted-by":"crossref","first-page":"10016","DOI":"10.1074\/jbc.M109.068759","article-title":"Physical interaction of Jab1 with human serotonin 6 G-protein-coupled receptor and their possible roles in cell survival","volume":"285","author":"Yun","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2020.108099_bib232","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejmech.2019.05.020","article-title":"Multi-target design strategies for the improved treatment of Alzheimer's disease","volume":"176","author":"Zhang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108099_bib233","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-neuro-080317-061725","article-title":"What happens with the circuit in Alzheimer's disease","volume":"41","author":"Zott","year":"2018","journal-title":"Annu. Rev. Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820301672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820301672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:03:21Z","timestamp":1758438201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390820301672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":233,"alternative-id":["S0028390820301672"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108099","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual-acting agents for improving cognition and real-world function in Alzheimer\u2019s disease: Focus on 5-HT6 and D3 receptors as hubs","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108099"}}